284 related articles for article (PubMed ID: 16495239)
21. Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus.
Wichelhaus TA; Schäfer V; Brade V; Böddinghaus B
Antimicrob Agents Chemother; 1999 Nov; 43(11):2813-6. PubMed ID: 10543773
[TBL] [Abstract][Full Text] [Related]
22. Bacteraemia with rifampin-resistant Staphylococcus aureus and the potential role of cross-resistance between rifampin and rifaximin.
Valentin T; Hoenigl M; Wagner J; Krause R; Zollner-Schwetz I
J Infect; 2014 Sep; 69(3):295-7. PubMed ID: 24780764
[No Abstract] [Full Text] [Related]
23. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci.
Robertson GT; Bonventre EJ; Doyle TB; Du Q; Duncan L; Morris TW; Roche ED; Yan D; Lynch AS
Antimicrob Agents Chemother; 2008 Jul; 52(7):2324-34. PubMed ID: 18443106
[TBL] [Abstract][Full Text] [Related]
24. The antibacterial activity of a new 3-azinomethyl-rifamycin.
Strippoli V; Bruzzese T; Galli R; Simonetti N; Tronci N
Farmaco Sci; 1988; 43(7-8):619-25. PubMed ID: 3147199
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.
Dickinson JM; Mitchison DA
Tubercle; 1987 Sep; 68(3):177-82. PubMed ID: 2834842
[TBL] [Abstract][Full Text] [Related]
26. New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases.
Combrink KD; Denton DA; Harran S; Ma Z; Chapo K; Yan D; Bonventre E; Roche ED; Doyle TB; Robertson GT; Lynch AS
Bioorg Med Chem Lett; 2007 Jan; 17(2):522-6. PubMed ID: 17070048
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of novel rifamycins against gram-positive clinical isolates.
Murphy CK; Karginova E; Sahm D; Rothstein DM
J Antibiot (Tokyo); 2007 Sep; 60(9):572-6. PubMed ID: 17917240
[TBL] [Abstract][Full Text] [Related]
28. Spiropiperidyl rifabutins: expanded in vitro testing against ESKAPE pathogens and select bacterial biofilms.
Cabal MP; Long TE; Turos E; García AB; Allen JL; Budny BG; Shaw LN
J Antibiot (Tokyo); 2020 Dec; 73(12):868-872. PubMed ID: 32651464
[TBL] [Abstract][Full Text] [Related]
29. In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin.
Woodley CL; Kilburn JO
Am Rev Respir Dis; 1982 Sep; 126(3):586-7. PubMed ID: 6289711
[TBL] [Abstract][Full Text] [Related]
30. In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus.
Tsuji BT; Yang JC; Forrest A; Kelchlin PA; Smith PF
J Antimicrob Chemother; 2008 Jul; 62(1):156-60. PubMed ID: 18400804
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and structure-activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin.
Jin Y; Gill SK; Kirchhoff PD; Wan B; Franzblau SG; Garcia GA; Showalter HD
Bioorg Med Chem Lett; 2011 Oct; 21(20):6094-9. PubMed ID: 21903392
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of rifapentine and other rifamycins against
Miller HK; Kersh GJ
Microbiol Spectr; 2024 Jul; 12(7):e0103424. PubMed ID: 38864598
[TBL] [Abstract][Full Text] [Related]
33. Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis.
Xia M; Suchland RJ; Carswell JA; Van Duzer J; Buxton DK; Brown K; Rothstein DM; Stamm WE
Antimicrob Agents Chemother; 2005 Sep; 49(9):3974-6. PubMed ID: 16127086
[TBL] [Abstract][Full Text] [Related]
34. Rifaximin intake leads to emergence of rifampin-resistant staphylococci.
Valentin T; Leitner E; Rohn A; Zollner-Schwetz I; Hoenigl M; Salzer HJ; Krause R
J Infect; 2011 Jan; 62(1):34-8. PubMed ID: 21073894
[TBL] [Abstract][Full Text] [Related]
35. Antibiofilm and intraosteoblastic activities of rifamycins against Staphylococcus aureus: promising in vitro profile of rifabutin.
Abad L; Josse J; Tasse J; Lustig S; Ferry T; Diot A; Laurent F; Valour F
J Antimicrob Chemother; 2020 Jun; 75(6):1466-1473. PubMed ID: 32125419
[TBL] [Abstract][Full Text] [Related]
36. Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus: an in vitro study.
Munckhof WJ; Kleinschmidt SL; Turnidge JD
Int J Antimicrob Agents; 2004 Dec; 24(6):605-8. PubMed ID: 15555885
[TBL] [Abstract][Full Text] [Related]
37. Rifamycins--obstacles and opportunities.
Aristoff PA; Garcia GA; Kirchhoff PD; Showalter HD
Tuberculosis (Edinb); 2010 Mar; 90(2):94-118. PubMed ID: 20236863
[TBL] [Abstract][Full Text] [Related]
38.
Albano M; Karau MJ; Greenwood-Quaintance KE; Osmon DR; Oravec CP; Berry DJ; Abdel MP; Patel R
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451499
[TBL] [Abstract][Full Text] [Related]
39. Emergence of rifampicin resistance during rifampicin-containing treatment in elderly patients with persistent methicillin-resistant Staphylococcus aureus bacteremia.
Lai CC; Tan CK; Lin SH; Liao CH; Huang YT; Hsueh PR
J Am Geriatr Soc; 2010 May; 58(5):1001-3. PubMed ID: 20722839
[No Abstract] [Full Text] [Related]
40. Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence.
O'Neill AJ; Huovinen T; Fishwick CW; Chopra I
Antimicrob Agents Chemother; 2006 Jan; 50(1):298-309. PubMed ID: 16377701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
